突发性耳聋伴眩晕的临床分析

目的 探讨突发性耳聋（简称突聋）伴良性阵发性位置性眩晕（BPPV）或突聋伴眩晕综合征（非BPPV）与突聋不伴眩晕的临床特征及疗效。方法 选取2018年1月—2019年12月收治的400例突聋患者,根据是否伴有眩晕症状,分为突聋伴眩晕组（163例）和突聋不伴眩晕组（237例）两组。163例突聋伴眩晕组患者进一步分为突聋伴BPPV组（97例）和突聋伴非BPPV组（66例）。所有入院患者行纯音测听、声导抗、耳声发射检查,根据不同听力曲线采用分型治疗,记录不同分组的听力疗效。结果 突聋伴BPPV组与突聋伴非BPPV组比较,两组听力有效改善率无统计学意义（P>0.05）;突聋不伴眩晕组听力有效改善率明显高于突聋伴BPPV组及突聋伴非BPPV组（P<0.05）。结论 对于突聋伴BPPV或突聋伴非BPPV,其听力疗效基本一致,突聋伴BPPV或突聋伴非BPPV患者,眩晕是影响其听力疗效及预后的关键因素之一。     

特发性水平半规管良性阵发性位置性眩晕复发相关因素分析

目的 研究特发性水平半规管良性阵发性位置性眩晕(HSC-BPPV)复位次数、前庭冷热试验、复位后残余眩晕是否与复发率存在关系。方法 2016年1月—2018年1月门诊手法复位成功的84例特发性HSC-BPPV的患者纳入本研究,所有患者均行Barbecue滚转手法复位。根据复位次数分为A组(<3次)和B组(≥3次);根据患者复位后有无残余眩晕,分为C组(无残余眩晕)和D组(残余眩晕),观察复发率。所有患者均行前庭冷热试验检查。结果 本研究显示A组(20.9%)与B组(26.8%)的复发率无明显差异;C组(11.8%)与D组(32.0%)复发率差异具有统计学意义(P=0.033);复位后存在残余眩晕患者前庭功能异常率高;复位后存在残余眩晕并伴有前庭冷热试验异常的患者复发率最高(66.7%);复发率最低的为复位次数<3次且复位后无残余眩晕的患者(6.3%)。结论 HSC-BPPV复发率与复位次数无关,冷热试验异常与残存眩晕相关,复位后残余眩晕伴前庭冷热试验异常提示患者复发率增高。     

良性阵发性位置性眩晕患者复位治疗后复发相关因素调查及站立平衡功能分析

目的 探讨良性阵发性位置性眩晕(BPPV)患者复位治疗后复发的因素,分析BPPV患者站立平衡功能。方法 选择2019年2月—2020年12月收治的209例BPPV患者,所有患者手法复位治疗后均接受定期电话随访,根据随访期间是否发生复发将患者分为复发组(48例)和无复发组(161例)。通过收集临床资料,采用多因素Logistic回归分析BPPV复发的危险因素。选择60例体检者为对照组,采用感觉整合试验(SOT)评估动态站立平衡功能,采用感觉相互作用与平衡的改良临床试验(mCTSIB)评估静态站立平衡功能,并比较BPPV组累及不同半规管患者以及对照组间动态和静态站立平衡功能差异性。结果 复发组年龄≥50岁、女性、高血压、高脂血症、糖尿病、眩晕持续时间≥1周、复位次数≥3次比例高于无复发组(P＜0.05)。多因素Logistic回归分析结果示年龄≥50岁、女性、糖尿病、高血压、高脂血症是BPPV手法复位后复发的危险因素(P＜0.05)。BPPV组累及后半规管患者睁眼-测力板稳定-视景随动(CON₃)、睁眼-测力板随动-视景稳定(CON₄)、闭眼-测力板随动-视景稳定(CON₅)、睁眼-测力板随动-视景随动(CON₆)SOT平衡得分低于对照组(P＜0.05),站立于海绵垫睁眼和闭眼时重心晃动的平均速度大于对照组(P＜0.05)。结论 年龄≥50岁、女性、高血压、高脂血症、糖尿病是BPPV手法复位后复发的危险因素,累及后半规管的BPPV患者可能容易发生站立平衡功能异常。     

单侧全聋型突发性聋患者临床特征及预后分析

目的 分析单侧全聋型突发性聋的一般临床特征,探讨影响预后的相关因素。方法 回顾2019年9月—2021年5月收治住院治疗的127例单侧全聋型突发性聋患者的临床资料,包括一般情况、伴随症状、伴发疾病、实验室检查、治疗效果等,采用χ²检验及二元Logistic回归分析患者性别、年龄、患耳侧别、发病至就诊时间、伴发疾病（高血压、糖尿病、心脏病）、伴随症状（耳鸣、眩晕/头晕）、实验室检查（叶酸、维生素B12、同型半胱氨酸）对预后的影响。结果 127例单侧全聋型突发性聋患者,伴耳鸣者113例（88.98%）,伴眩晕/头晕者91例（71.65%）,总有效率为41.73%。单因素分析显示患者的年龄（P=0.016）、发病至就诊时间（P=0.003）及是否伴眩晕/头晕（P=0.017）与预后相关,差异均具有统计学意义。患者的性别、患耳侧别、伴发基础疾病（高血压、糖尿病、心脏病）、耳鸣、实验室检查（叶酸、维生素B12、高同型半胱氨酸）对预后影响差异无统计学意义。多因素分析显示患者发病至就诊时间（P=0.006）、是否伴眩晕/头晕（P=0.037）为预后的独立危险因素,发病至就诊时间≥3 d组是<3 d组有效率的0.311倍（OR=0.311,95%CI为0.134~0.720,P=0.006）,伴眩晕/头晕者有效率是不伴者有效率的0.385倍（OR=0.385,95%CI为0.157~0.944,P=0.037）。结论 单侧全聋型突发性聋常伴耳鸣、眩晕/头晕,年龄≥40岁、发病至就诊时间≥3 d、伴眩晕/头晕提示预后不佳,其中发病至就诊时间≥3 d以及伴发眩晕/头晕为其独立危险因素,可为临床预后评判及治疗提供理论依据。     

人乳头状瘤病毒相关口咽鳞状细胞癌的特点及临床分析

目的 分析人乳头状瘤病毒（HPV）相关口咽鳞状细胞癌（OPSCC）的临床特点,探讨不同治疗方案对OPSCC患者生活质量的影响,以期更好地指导制定临床治疗方案并判断预后。方法 收集2014年1月-2019年1月在北京友谊医院诊治的38例OPSCC患者临床资料,男31例,女7例;其中扁桃体癌24例、舌根癌14例;HPV阳性患者13例,阴性患者25例;I、II期患者10例,III、IV期患者28例。38例患者中行同步放化疗4例,单纯根治性放疗2例,手术加术后放疗或放化疗27例,诱导化疗+术前放疗+手术或术后补充放疗5例。采用χ²检验分析HPV感染的临床特点,采用Kaplan-Meier法、Log-rank单因素分析和Cox回归模型多因素分析法计算生存率和预后相关因素分析;非参数秩和检验进行生活质量分析。结果 在OPSCC患者中,非吸烟、饮酒患者HPV阳性率更高（P=0.014,P=0.049）,HPV相关OPSCC患者更易发生颈部淋巴结转移（P=0.032）。HPV阳性以及肿瘤分期I、II患者总生存率更高（P=0.003,P=0.006）,且为影响患者预后的独立危险因素。3种治疗方案患者总生存率差异无统计学意义（P>0.05）,但同步放化疗患者吞咽功能障碍更显著,差异存在统计学意义（P=0.002）。结论 HPV相关OPSCC患者中多为非吸烟、饮酒的人群,更容易发生颈部淋巴结转移,但预后相对较好。可考虑降级治疗以保护患者的吞咽功能,改善治疗后的生活质量。     

巴曲酶联合常规治疗对不同类型突发性聋患者的疗效观察

目的 观察巴曲酶联合常规治疗在不同听力损失类型的突发性聋患者治疗中的临床疗效。方法 回顾性分析121例（135耳）不同听力损失类型的突发性聋患者的临床资料。按照患者病历资料中是否规范地加用巴曲酶治疗将患者分为常规治疗组69例（79耳）与巴曲酶组52例（56耳）,常规治疗组应用激素、营养神经、扩血管药物;巴曲酶组在常规治疗基础上加用巴曲酶注射液。观察两组治疗1周后患者听力改善情况。结果 巴曲酶组总有效率为64.29%,高于常规治疗组（P=0.001）;低频下降型突聋患者巴曲酶组有效率为90.91%,高于常规治疗组（P=0.149）;高频下降型突聋患者巴曲酶组有效率为60.00%,高于常规治疗组（P=0.037）;平坦型突聋患者巴曲酶组有效率为41.67%,常规治疗组的有效率为44.83%,两组差异具有统计学意义（P=0.853）;全聋型突聋患者巴曲酶组有效率为65.22%,高于常规治疗组（P=0.025）。结论 巴曲酶联合常规治疗方式能有效改善突发性聋患者,尤其是高频下降型及全聋型患者听力水平。     

鳞状细胞癌抗原在慢性鼻窦炎伴鼻息肉患者血清中的表达及组织分型中的意义

目的探讨鳞状细胞癌抗原(SCCA)在慢性鼻窦炎伴鼻息肉(CRSwNP)患者血清中的表达情况及其在组织分型中的应用价值。方法选取74例CRSwNP患者以及40例健康志愿者作为研究对象,根据CRSwNP患者术后组织病理切片中嗜酸性粒细胞浸润情况将CRSwNP分为非嗜酸性CRSwNP组(non-eCRSwNP,n=33)和嗜酸性CRSwNP组(eCRSwNP,n=41)。术前收集入组患者的外周血检测SCCA在血清中的浓度,观察其与临床指标的联系及其在不同组织分型患者中浓度差异。结果与对照组相比,CRSwNP组患者血清SCCA表达水平显著升高(P＜0.000 1);与non-eCRSwNP组相比,eCRSwNP组患者血清SCCA表达水平显著升高(P＜0.000 1)。CRSwNP患者血清SCCA浓度与外周血嗜酸性粒细胞计数(r=0.404,P=0.000 4)、组织嗜酸性粒细胞比例(r=0.283,P=0.015)均呈正相关。二元Logistic回归及受试者工作曲线(ROC)分析提示血清SCCA水平与CRSwNP组织亚型具有明显的相关性并能较好地将两者进行区分[曲线下面积(AUC)=0.844,P=0.000]。结论CRSwNP患者血清SCCA表达上调且与组织嗜酸性炎症相关,其表达水平可能有助于术前鉴别CRSwNP亚型。     

29例外伤性大脑半球间硬膜下血肿的临床分析

目的 探讨外伤性大脑半球间硬膜下血肿(TISH)的治疗方法和预后。方法 回顾性分析华中科技大学同济医学院附属同济医院2014年8月—2019年5月收治的29例TISH患者的临床资料。患者治疗后2周由Glasgow预后量表(GOS)评估短期疗效。GOS 1~3分为疗效差,GOS 4~5分为疗效好。结果 疗效良好者20例,占69.0%,疗效差者9例,占31.0%。疗效好组治疗后2周Glasgow昏迷评分(GCS)平均为(14.6±0.7)分,疗效差组为(9.4±2.2)分,两组间比较差异具有统计学意义(P＜0.001)。单因素分析显示影响TISH疗效的因素包括合并合并脑挫裂伤(P=0.032),入院时GCS评分(P＜0.001),住院期间病变变化(P=0.049),住院期间GCS极低值(P＜0.001),治疗方式(P=0.016)和手术方式(P＜0.05)。重症TISH患者(GCS≤8分)中7例行手术治疗,3例非手术治疗。手术组预后良好者4例,预后差者3例;而非手术组3例患者短期预后均较差。结论 TISH临床少见,多数患者病情较轻经保守治疗效果较好。部分患者出现迟发性出血,颅内压增高,神经功能障碍等,需严密监护。重症TISH患者手术治疗能够改善预后。     

舌骨位置与多导睡眠监测指标及腭咽成形术后疗效的相关性分析

目的研究阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者舌骨位置与多导睡眠监测(PSG)参数指标以及腭咽成形手术疗效相关性,探讨舌骨位置对OSAHS患者疾病程度及腭咽成形手术预后的影响。方法收集2020年6月—2021年10月47例不同程度OSAHS行改良悬雍垂腭咽成形术(H-UPPP)患者术前上气道CT影像及术前、术后3个月PSG数据资料,回顾性分析颏下点至舌骨下缘的垂直距离(MH-v)、下颌骨颏棘至舌骨水平距离(MH-h)以及Friedman舌位(FTP)与阻塞性睡眠呼吸暂停低通气指数(AHI)、平均血氧饱和度(AvSpO₂)、最低血氧饱和度(LSpO₂)及血氧饱和度低于90%累积时间占总睡眠时间比(CT90)相关性,并进一步分析FTP、MH-v与H-UPPP手术疗效的相关性。结果MH-v与AHI、LSpO₂和AvSpO₂均呈中等程度相关(r=0.540, P=0.000;r=-0.523, P=0.000;r=-0.514, P=0.000),MH-v与CT90呈弱相关(r=0.495,P=0.000);MH-h与上述PSG指标均无相关性(P＞0.05);FTP与AHI、LSpO₂、AvSpO₂及CT90均呈弱相关(ρ=0.329, P=0.024;ρ=-0.309, P=0.034;ρ=-0.370, P=0.01;ρ=0.325, P=0.026)。在H-UPPP手术有效组与无效组的MH-h比较差异无统计学意义(t=-0.448,P=0.656),MH-v差异具有统计学意义(t=-5.908, P=0.000),而两组之间FTP比较差异无统计学意义(χ²=1.540,P=0.215),MH-v受试者工作特征ROC曲线下面积为0.884,在预测H-UPPP手术有效性方面具有中等诊断价值。结论作为影响OSAHS患者病情的解剖学因素,CT影像中的舌骨位置MH-v相比FTP与PSG诸多指标具有更好的相关性,对预测H-UPPP手术有效性具有一定的价值。     

甲状腺乳头状癌患者甲状腺肿瘤特征对颈侧区淋巴结转移的影响

目的 研究甲状腺乳头状癌患者甲状腺肿瘤特征对颈侧区淋巴结转移的预测作用。方法 回顾性分析2017年1月—2020年12月手术治疗的甲状腺乳头状癌患者的临床资料509例,男105例,女404例;年龄18~85岁,平均(45.38±14.85)岁。其中临床分期Ⅰ期382例,Ⅱ期127例。采用多因素二元Logistic回归分析甲状腺乳头状癌患者颈侧区淋巴结转移的影响因素。结果 根据病理诊断结果是否存在颈侧区淋巴结转移,其中178例患者存在颈侧区淋巴结转移,331例患者不存在颈侧区淋巴结转移。存在颈侧区转移和不存在颈侧区转移的患者临床资料比较发现,存在颈侧区转移的患者中年龄<40岁、肿瘤最大直径>2 cm、转移中央区淋巴数量>5个、多灶性以及鼠类肉瘤滤过性毒菌致癌基因同源体B1(v-raf murine sarcoma viral oncogene homolog B1,BRAF)不存在突变的患者比例显著高于存在颈侧区转移的患者(P<0.05)。采用多因素二元Logistic回顾分析结果发现肿瘤最大直径>2 cm (OR=3.482,95%CI:1.482~5.642,P=0.000)、转移中央区淋巴结数量>5个(OR=6.583,95%CI:2.384~12.373,P=0.000)、多灶性(OR=3.473,95%CI:1.387~8.684,P=0.032)以及BRAF不存在突变(OR=3.952,95%CI:1.489~9.572,P=0.000)是甲状腺乳头状癌发生颈侧区淋巴结转移的独立危险因素。结论 肿瘤最大直径>2 cm、转移中央区淋巴数量>5个、多灶性以及BRAF不存在突变是甲状腺乳头状癌患者出现颈侧区淋巴结转移的独立危险因素。     

Caloric tests in clinical practice in benign paroxysmal positional vertigo

Background: The value of caloric tests in benign paroxysmal positional vertigo (BPPV) patients is unclear.

Objectives: To analyze the features and clinical significance of caloric tests in BPPV patients.

Materials and methods: About 2192 patients (256 BPPV and 1936 non-BPPV) who complained of dizziness triggered by movement, accompanied by the symptom of hearing loss or a history of vertigo, participated in this prospective clinical study. All subjects received a caloric test, 213 BPPV patients underwent follow-up for at least 6 months after canalith repositioning procedures (CRPs).

Results: (1) The abnormal canal paresis (CP) prevalence of BPPV was 57%. (2) The curative rate of single CRP decreased during follow-up from 90.1% after 7 days to 61% after 6 months and was significantly lower in patients with (54.1%) than in those without (70.1%) an abnormal CP at 6 months post-treatment (p?=?.01). (3) The recurrent rate was significantly higher in BPPV patients with abnormal CP (25.2%) than with normal CP (12.5%; p?=?.017).

Conclusions and significance: Patients with abnormal CP needed more CRPs and were more prone to relapse. The value of the caloric test in treatment planning and predicting recurrence in BPPV patients should be emphasized.     

Correlation between serum vitamin D level and benign paroxysmal positional vertigo recurrence

ObjectiveBenign paroxysmal positional vertigo (BPPV) is the most common cause of dizziness in the general population. BPPV is known to be closely related to the serum vitamin D level. This study aimed to examine the relationship between serum vitamin D levels and BPPV recurrence.MethodsA retrospective chart review was conducted on 50 patients diagnosed with posterior and lateral canal BPPV. The diagnosis of BPPV was based on the finding of vertigo and nystagmus induced by certain head positions (The Dix–Hallpike maneuver and head roll tests). The patients were classified into BPPV recurrence (Group A) and non-recurrence groups (Group B). Otolith function was assessed by cervical vestibular evoked myogenic potential (cVEMP) and ocular vestibular evoked myogenic potential (oVEMP), and their association with vitamin D levels was evaluated.ResultsThere were 19 subjects in Group A and 31 in Group B. There were no significant differences in age, sex, cVEMP, and oVEMP between the two groups. The average vitamin D level was 12.9 ± 8.0 ng/mL for Group A and 19.2 ± 8.2 ng/mL for Group B, and the difference between the groups was significant (p = 0.011). In the receiver operating characteristic curve analysis for BPPV recurrence with the best sensitivity and specificity, the optimal cut-off value of total serum vitamin D was determined as 12.74 ng/mL. Furthermore, reclassifying the patients based on the cut-off value showed a significantly higher recurrence rate in the group with a lower serum vitamin D level (70.5% vs. 22.5%, p = 0.007).ConclusionThis complex finding highlights the importance of measuring serum vitamin D levels to monitor and evaluate patients at risk of BPPV recurrence.     

Comparison between objective and subjective benign paroxysmal positional vertigo: clinical features and outcomes

Conclusions: Objective benign paroxysmal positional vertigo (O-BPPV) and subjective BPPV (S-BPPV) have similar demographic and clinical features. Canalith repositioning manoeuvres (CRMs) can be an effective treatment for patients with S-BPPV, and a diagnosis of positional nystagmus is not essential for considering CRMs. This study supports the use of CRMs as the primary treatment for S-BPPV.

Objective: To examine differences in demographic and clinical features, as well as treatment outcomes, between O-BPPV and S-BPPV.

Methods: The medical records of 134 patients with BPPV were reviewed for demographic characteristics, past medical history, associated symptoms, response to CRMs, interval between symptom onset and the first medical visit, and recurrence rate. The O-BPPV group (n?=?101) comprised patients who experienced vertigo and accompanying autonomic symptoms, and showed typical nystagmus. The S-BPPV group (n?=?33) comprised patients who, when subjected to a provoking manoeuvre, showed all of the classic BPPV symptoms but did not show nystagmus. All patients had at least 3 years of follow-up.

Results: The demographics (age and sex ratio), past medical history, and associated symptoms were not significantly different between the two groups. Posterior semi-circular canal BPPV appeared more than twice as often as horizontal semi-circular canal BPPV in patients with S-BPPV. However, both canals were affected to a similar proportion in patients with O-BPPV, and the difference was marginally significant (p?=?0.073). Overall improvement was better in O-BPPV than in S-BPPV; however, there was no significant difference. The total numbers of manoeuvres for recovery and the interval between symptom onset and the first medical visit also did not show any significant inter-group differences. During a 3-year follow-up, the recurrence rate was 13.8% for O-BPPV and 21.2% for S-BPPV.     

Clinical characteristics and treatment outcomes for benign paroxysmal positional vertigo comorbid with hypertension

Conclusions: Patients with BPPV comorbid with hypertension (h-BPPV) tend to receive a delayed diagnosis of BPPV. Comorbidity with hypertension did not influence the efficacy of the repositioning maneuver; however, comorbidity with hypertension was associated with an increased recurrence rate of BPPV.

Objectives: To determine the clinical characteristics and outcomes of h-BPPV, as well as the clinical differences between h-BPPV and idiopathic BPPV (i-BPPV).

Methods: The authors reviewed the medical records of 41 consecutive patients with h-BPPV (the h-BPPV group) from March to December 2014 and 47 patients with i-BPPV (the i-BPPV group) during the same period.

Results: There were no significant differences in age, sex ratio, or the affected side between the h-BPPV and i-BPPV groups. The proportion of patients reporting an initial episode of positional vertigo was significantly lower in the h-BPPV group (51.22% vs 74.47%; p?=?.024). Patients in the h-BPPV group reported a longer median episode duration than did those in the i-BPPV group (60 days vs 15 days; p?=?.017). The results of treatment using repositioning maneuvers were similar between the two groups. At follow-up, 13 patients in the h-BPPV group were diagnosed with recurrent BPPV compared with six in the i-BPPV group (p?=?.031).     

Patient,disease, and outcome characteristics of benign paroxysmal positional vertigo with and without Meniere’s disease

Abstract

Background: Meniere’s disease (MD)-associated benign paroxysmal positional vertigo (BPPV) is complex and difficult to diagnose, and reports of its prevalence, pathologic features and outcomes are sparse and conflicting.

Objective: Report disease characteristics and outcomes associated with the presence of MD in patients with BPPV.

Materials/methods: A retrospective study of patients with BPPV between 2007 and 2017 at a single, high-volume institution.

Results: Of 1581 patients with BPPV identified, 7.1% had MD and 71.9% of those patients had BPPV in the same ear(s) as MD. Patients with MD were more likely to have lateral semicircular canalithiasis (11.6% vs. 5.5%, p?=?.009) and multiple canalithiasis (7.1% vs. 2.5%, p?=?.005). MD was associated with an increased rate of resolution of BPPV (p?=?.008) but also increased time to resolution (p?=?.007). There was no association between MD and recurrence of BPPV.

Conclusions: MD is associated with lateral canalithiasis. Contrary to prior reports, BPPV in MD can affect either ear and was not associated with poorer outcomes than idiopathic BPPV.

Significance: The largest series to date investigating disease and outcome characteristics for BPPV in MD is presented. These data inform diagnosis and expectations in the management of these complex patients.     

Efficacy of BPPV diagnosis and treatment system for benign paroxysmal positional vertigo

ObjectivesTo evaluate the efficacy of automatic benign paroxysmal positional vertigo (BPPV) diagnosis and treatment system for BPPV compared with the manual repositioning group.MethodsTwo hundred thirty patients diagnosed as idiopathic BPPV who were admitted from August 2018 to July 2019 in Zhejiang Hospital were included. Among them, 150 patients of posterior semicircular canal BPPV(pc-BPPV), 53 patients of horizontal semicircular canal BPPV(hc-BPPV), and 27 patients of horizontal semicircular canal calculus (hc-BPPV-cu) were randomly treated with BPPV diagnosis and treatment system(the experimental group) or manual repositioning (the control group). Resolution of vertigo and nystagmus on the Dix-Hallpike and Roll test on day 3,day 7,day 14 and day 28 follow-up after first treatment was the main outcome measure to assess the efficacy of treatment.ResultsAt 3-day and 7-day follow-up after treatment with BPPV diagnosis and treatment system, 79%, 91%had complete resolution of vertigo and nystagmus, the effective rate in the experimental group were significantly higher than those in the control group, the differences were statistically significant(P < .05). On day 14, the effective rate in the experimental group (96%) was slightly higher than that in the control group(91%), but there was no significant difference between the two groups. And at 28-day after the first treatment, the effective rate was 100% in the experimental group and the control group. The repositioning efficiency of pc-BPPV (the first, second, third treatment), hc-BPPV (the first, second, third treatment), hc-BPPV-cu(the first, second treatment) in the experimental group were higher than the control group, and the secondary reposition of pc-BPPV in the experimental group was significantly higher than the control group(96%vs.84%; P < .05). While for the hc-BPPV-cu patients, the effective rate of the third treatment in the experimental group was slightly lower than that of the control group, but the differences were not statistically significant.ConclusionsBPPV diagnosis and treatment system is effective for the treatment of BPPV, with a better effective rate than those treated with manual maneuver, and is safe and easy to perform on patients.     

Asociación entre el hydrops endolinfático y vértigo posicional paroxístico benigno: ¿casualidad o causalidad?

IntroductionThe aim of this study was to determine the prevalence of benign paroxysmal positional vertigo (BPPV) in patients diagnosed with endolymphatic hydrops (EH) and to analyze whether this association is a factor for poor prognosis in these patients.Material and methodsA retrospective study was carried out in our department among the patients definitively diagnosed as having Ménière's disease according to the criteria of the American Academy of Otolaryngology and BPPV by the usual triggering manoeuvres.ResultsThe prevalence of BPPV in our patients with EH was 5.1%. The rate of cure with the repositioning manoeuvres is 90.9%, however success with the first manoeuvre was only 63.36%. Recurrences occurred in up to 22.22%. We found a lower success rate with the first manoeuvre in relation to the rest of the patients with BPPV without EH. This difference is statistically significant (P=0.042).DiscussionWe did not find that these patients to have a lower rate of cure with the repositioning manoeuvres or a higher rate of recurrence. But in our protocol the first manoeuvre had a lower success rate than in the rest of the patients.     

Effects of Semont maneuver on benign paroxysmal positional vertigo: a meta-analysis

Background: Benign paroxysmal positional vertigo (BPPV) is the most common type of peripheral vertigo. This study aimed to evaluate the effects of the Semont maneuver (SM) for BPPV treatment, compared with other methods.

Methods: Studies were selected in relevant databases under pre-defined criteria up to June 2015. The Cochrane evaluation system was used to assess the quality of the studies. Effect size was indicated as a risk-ratio (RR) with corresponding 95% confidential interval (CI). Statistical analysis was conducted under a randomized- or fixed-effects model. Sub-group analysis was performed.

Results: Ten studies were included in the meta-analysis. All of the studies presented a low attrition bias, but a high selection and reporting bias. SM had a much higher recovery rate (SM vs no treatment: RR?=?2.60, 95% CI?=?1.97–3.44, p?p?p?Conclusion: SM is as effective as EM and BDE for BPPV treatment.